From the Journals

MACE risk similar across arthritis subtypes


 

FROM ARTHRITIS CARE & RESEARCH

Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis were linked to similarly increased risks of major adverse cardiovascular events in a large population-based cohort study.

Inflammation itself drives this relationship and “adequate control of disease activity is needed to lower cardiovascular risk,” wrote Kim Lauper, MD, of Geneva University Hospitals, and her coinvestigators.

Major adverse cardiovascular events (MACE) also were significantly associated with traditional cardiovascular risk factors such as smoking, hypertension, and hyperlipidemia, “stressing the importance of [their] detection and management,” the researchers wrote in Arthritis Care and Research.

Previous studies linked inflammatory arthritis to a 40%-50% increase in risk of cardiovascular events, such as MI and acute coronary syndrome. Inflammatory arthritis also increases the risk of cerebrovascular disease, and traditional cardiovascular risk factors alone do not explain these associations, the researchers noted. Mounting data suggest that inflammation underlies the pathogenesis of atherosclerosis. Other studies have documented the cardioprotective effect of disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis and psoriasis.

Dr. Lauper and her coinvestigators examined the prevalence and incidence of MACE, including MI, transient or permanent cerebrovascular events, or cardiovascular deaths among patients with rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis. The 5,315 patients in the study were part of the Swiss Clinical Quality Management registry, which longitudinally tracks individuals throughout Switzerland who receive biologic DMARDs.

The investigators also asked rheumatologists to supply missing data and used a questionnaire to survey patients about cardiovascular events and associated risk factors. These efforts produced more than 66,000 patient-years of follow-up data, more than half of which were for rheumatoid arthritis and less than 10,000 of which were for psoriatic arthritis.

Pages

Recommended Reading

Here comes bimekizumab, the newest IL-17 inhibitor
MDedge Family Medicine
Ustekinumab quells aortic inflammation in patients with severe psoriasis
MDedge Family Medicine
Xeljanz: FDA panel recommends ulcerative colitis indication
MDedge Family Medicine
Arthritis limits physical activity the most in the South
MDedge Family Medicine
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Family Medicine
Study using U.K. data quantifies infection risk associated with psoriasis
MDedge Family Medicine
TB in 2017: Good news and bad news
MDedge Family Medicine
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Family Medicine
Reassurance for women taking certolizumab during pregnancy
MDedge Family Medicine
AbbVie, Samsung Bioepis settle suits with delayed U.S. entry for adalimumab biosimilar
MDedge Family Medicine